We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Preventing Rheumatoid Arthritis Requires a Mixed Population of Regulatory T-cells

By LabMedica International staff writers
Posted on 23 May 2012
A recent article discussed the latest thinking regarding the molecular aspects of how the immune system guards itself from the development of autoimmune disorders such as rheumatoid arthritis and why this system sometimes fails.

A white blood cell cocktail containing CD4+CD25+Foxp3+ regulatory T-cells (Tregs) is required to restrain the immune system from mounting an autoaggressive systemic inflammatory response. More...
Rheumatoid arthritis is an autoimmune disorder that occurs when this protection fails and the immune system attacks the synovium, the membrane that lines all the joints of the body. It is a common disorder that causes pain, redness, and swelling around the joints. It has been estimated that approximately one percent of the adult population, worldwide, suffers from rheumatoid arthritis.

Investigators at The Wistar Institute (Philadelphia, PA; USA) used a mouse model of spontaneous autoimmune arthritis. These animals had been genetically engineered to express a “self” molecule - a clonotypic T-cell receptor (TCR) - that induced arthritis by an IL-17–dependent mechanism. The investigators then determined how TCR specificity contributed to Treg activity.

Results published in the May 1, 2012, issue of the Journal of Immunology revealed that administration of polyclonal Tregs suppressed Th17 cell formation and prevented arthritis development. Treatment with Tregs that expressed only the clonotypic TCR did not prevent development of arthritis.

“Our results show, surprisingly, that suppressing the immune response against a single target will not shut down the inflammatory response that causes rheumatoid arthritis,” said senior author Dr. Andrew J. Caton, professor in The Wistar Institute’s tumor microenvironment and metastasis program. “Instead, an array of inflammation-stimulating antigens may be involved in causing the disease, since our study shows that an array of regulatory T-cells is required to temper the immune system’s attack on joints.”

“The big unanswered question of rheumatoid arthritis is ‘why are joints targeted’?” said Dr. Caton. “Of all the tissues in the body, of all the places our immune system could attack, this question remains. One idea is that the immune system is not deliberately attacking joints in patients with rheumatoid arthritis, but the joint inflammation is a side effect of the natural tendency of these cells to accumulate in these areas of the body.”

Related Links:

The Wistar Institute



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.